Top analysts change outlook on top names. Baird, Canaccord Genuity, Needham, Stifel, Truist Securiti

Canaccord Genuity analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Buy and raises the pri

PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividen

ABN Amro Investment Solutions boosted its stake in AbbVie Inc. (NYSE: ABBV) by 80.6% in the undefine

AbbVie (ABBV) closed at $256.18 in the latest trading session, marking a +1.11% move from the prior

It looks like a great buy-and-hold option.

IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-wei

FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approac

Baader Bank Aktiengesellschaft grew its holdings in AbbVie Inc. (NYSE: ABBV) by 560.7% in the first

Andra AP fonden lifted its holdings in AbbVie Inc. (NYSE: ABBV) by 44.2% during the first quarter, a

REGENXBIO announced positive long-term sura-vec trial data for wet AMD and diabetic retinopathy, alo

PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yie

IXJ offers broader diversification with 110 holdings and a lower 0.40% expense ratio, while PJP's co

Dimensional Fund Advisors LP lowered its stake in AbbVie Inc. (NYSE: ABBV) by 10.5% during the undef

AbbVie will fund this acquisition with debt, leaving its cash reserves intact. The company should ma

The three biggest US pharma names by market cap trade at very different setups right now: Johnson &

AIA Group Ltd raised its position in shares of AbbVie Inc. (NYSE: ABBV) by 23.4% in the undefined qu

Allspring Global Investments Holdings LLC boosted its position in shares of AbbVie Inc. (NYSE: ABBV)

AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.69% on an annualized basi

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the European Commission has approved

Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved

ABBV's neuroscience business is expected to post solid Q2 growth, with key brands and Vyalev in focu

UnitedHealth's (UNH) strong earnings and raised outlook lifted healthcare ETFs despite a sharp d

AbbVie ABBV stock has risen 8.9% so far this year as investor confidence strengthened in the company

Citigroup analyst Geoff Meacham maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exp

Both AbbVie (NYSE:ABBV | ABBV Price Prediction) and Baxter International (NYSE:BAX) flashed the same

UBS analyst Michael Yee maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target f

BMO Capital analyst Evan David Seigerman maintains AbbVie (NYSE:ABBV) with a Outperform and raise

B of A Securities analyst Geoff Meacham maintains AbbVie (NYSE:ABBV) with a Buy and raises the pr

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

RBC Capital analyst Trung Huynh maintains AbbVie (NYSE:ABBV) with a Outperform and raises the pri

Wells Fargo analyst Mohit Bansal maintains AbbVie (NYSE:ABBV) with a Overweight and raises the pr

Guggenheim analyst Vamil Divan maintains AbbVie (NYSE:ABBV) with a Buy and raises the price targe

JP Morgan analyst Chris Schott maintains AbbVie (NYSE:ABBV) with a Overweight and raises the pric

Scott urges Trump admin to increase tariffs on Chinese generic drug makers, citing forced labor &amp

Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2026 are expected to

TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based

Cantor Fitzgerald analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Overweight and raises

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.03% on an annualized basis

Genmab reports positive Phase 3 EPCORE DLBCL-4 results in relapsed lymphoma; analyst points to label

US lawmakers probe Merck and AbbVie over national security and ethical risks tied to clinical trials

Topline results from Phase 3 EPCORE® DLBCL-4 trial evaluating epcoritamab in combination with lenali

FDA approves AbbVie Skyrizi for pediatric psoriasis, while EU’s CHMP backs Rinvoq for vitiligo and a

If approved, upadacitinib is expected to be the first systemic medication for patients with non-segm

AbbVie (NYSE:ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI®

Major M&A deals this week include: Adobe buys Topaz Labs, Rise Baking Company purchases Jimmy&#3

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 4.21% on an annualized basis

AbbVie will acquire Apogee Therapeutics for $10.9 billion, with analyst citing long-term immunology

Piper Sandler analyst David Amsellem reiterates AbbVie (NYSE:ABBV) with a Overweight and maintain